FYR Bio

health AImedtechdiagnosticsprecision medicine

Raised$8.26 million

Employees16

LocationMissoula, MT

About

FYR is revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, trials, drugs and outcomes. FYR’s EV-Omics (EVO) platform leverages its proprietary technology, SPARCs, to enrich for extracellular vesicles from diseased cells and enable the deep assessment of proteins and nucleic acids from a simple blood draw. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanisms, thereby informing potential diagnostic and treatment options. The unparalleled view provided by FYR’s multiomic approach can transform personalized patient care, from screening through therapy selection and monitoring. For more, visit fyr.bio.

Product

Value proposition: AI-powered EV-Omics platform (EVO) enabling RNA and protein insights from blood to inform biomarker discovery, smarter trials, and personalized patient care.
Target customers: Biotech and pharma companies, diagnostic developers, clinical researchers

Founders

Chris Booth, Ph.D.
Sarjubhai Patel, Ph.D.

Products

EV-Omics (EVO) platformSPARCs enrichment technologyRNA and protein insights from blood

Key features

Enrichment of disease-associated extracellular vesicles (EVs)AI-enabled multi-omic analysisProteins and RNA profiling from bloodMolecular snapshots of diseaseSupport for discovery through clinical validationCustom data outputs and flexible engagement models

Technologies

EV-Omics (EVO)SPARCs technologyAI/multi-omics integrationExtracellular vesicle enrichment

Partnerships

Partner with FYR (from site)Collaborative approach for tailored study design

Investors

Sontag Innovation FundYuvaan Tiwari FoundationTwo Bear CapitalNational Cancer InstituteNational Science Foundation

News

FYR Closes $8 Million Financing to Advance Blood-Based Biomarkers Across Oncology and Neuroscience - FYR Bio · 2025-09-24T14:27:14.000Z
FYR Bio and NuvOx Therapeutics Awarded NCI Direct-to-Phase II SBIR Grant to Advance Liquid-Biopsy Collaboration in Phase IIb Glioblastoma Trial - FYR Bio · 2025-11-19T16:46:28.000Z
FYR lands funding to find new biomarkers for Parkinson's · 2025-09-26T16:52:43.000Z
FYR Enters Know-How Agreement with Mayo Clinic to Collaborate on Blood-Based Biomarker Solutions for Parkinson’s Disease - FYR Bio · 2025-04-29T13:12:21.000Z
FYR Integrates CIQ Fuzzball to Scale AI-Enabled Multiomic Platform and Accelerate Breakthroughs in Precision Medicine - FYR Bio · 2025-10-09T14:14:26.000Z
FYR Closes $8 Million Financing to Advance Blood ... - BioSpace · 2025-09-25T00:00:00.000Z

Browse similar startups

Related startups

Associated Dermatology & Skin Cancer Clinic — Helena, MT
Integrated Musculoskeletal Care, Inc. — Tallahassee, FL
Just Vital Solutions PLLC (Remote Patient Monitoring) — Houston, TX
KindHealth AI — Austin, TX
Metfora Diagnostics — Tucson, AZ
mobriseHealth Inc — Ashburn
Naviday Health — Boston, MA
G Medical Diagnostic Services, Inc — Austin, TX
Gala GLP 1 — San Francisco, CA
GAPhealth Technologies Inc — Durham, NC
GARDEN STATE HEART CARE, PC — Manalapan, NJ
GatherMed — New Orleans, LA

Profile updated Jul 29, 2026. Sources: fyr.bio, linkedin.com, outlook.office.com